Raghav Sundar
Cards
About
Research
Publications
2024
EORTC stomach cancer PD-L1 biomarker European initiative: the ASPIRE study protocol
Petrillo A, Oudijk L, Sundar R, Daumer C, Casas J, D’Haese D, Mauer M, van Grieken N, Smyth E, Moehler M. EORTC stomach cancer PD-L1 biomarker European initiative: the ASPIRE study protocol. ESMO Gastrointestinal Oncology 2024, 5: 100071. DOI: 10.1016/j.esmogo.2024.100071.Peer-Reviewed Original ResearchPersonalized dose selection for the first Waldenström macroglobulinemia patient on the PRECISE CURATE.AI trial
Blasiak A, Tan L, Chong L, Tadeo X, Truong A, Senthil Kumar K, Sapanel Y, Poon M, Sundar R, de Mel S, Ho D. Personalized dose selection for the first Waldenström macroglobulinemia patient on the PRECISE CURATE.AI trial. Npj Digital Medicine 2024, 7: 223. PMID: 39191913, PMCID: PMC11350179, DOI: 10.1038/s41746-024-01195-5.Peer-Reviewed Original ResearchArtificial intelligenceClinical decision support systemsDecision support systemIntegration of AIAI-enabled toolsWaldenstrom's macroglobulinemiaBruton tyrosine kinase inhibitor ibrutinibRare diseaseEnhance usersWaldenstrom's macroglobulinemia patientsKinase inhibitor ibrutinibSupport systemSecondary outcome measuresDiagnosed WMDigital health solutionsWM patientsInhibitor ibrutinibMacroglobulinemia patientsDosing recommendationsUsersManagement of rare diseasesClinical efficacyDevelopment of digital technologiesDose selectionPersonalized therapySpatially resolved niche and tumor microenvironmental alterations in gastric cancer peritoneal metastases
Zhao J, Johnny Ong C, Srivatsava S, Ann Chia D, Ma H, Huang K, Sheng T, Ramnarayanan K, Ong X, Tay S, Hagihara T, Keng Tan A, Ching Teo M, Tan Q, Ng G, Wee-Shan Tan J, Hsien Ng M, Gwee Y, Walsh R, Law J, Shabbir A, Kim G, Tay Y, Her Z, Leoncini G, Teh B, Hong J, Kiat Tay R, Teo C, Dings M, Bijlsma M, Yew Lum J, Mathur S, Pietrantonio F, Blum S, van Laarhoven H, Klempner S, Yong W, Yan So J, Chen Q, Tan P, Sundar R. Spatially resolved niche and tumor microenvironmental alterations in gastric cancer peritoneal metastases. Gastroenterology 2024 PMID: 39147169, DOI: 10.1053/j.gastro.2024.08.007.Peer-Reviewed Original ResearchA phase Ib/II study of pacritinib, an interleukin 1 receptor associated kinase 1 (IRAK1) inhibitor, in patients (pts) with solid tumors harboring the 1q21.3 copy number amplification (CNA).
Lim J, Aau M, Yeong J, Goh B, Yong W, Soo R, Wong A, Tan D, Chee C, Sundar R, Jeyasekharan A, Wong C, Chen P, Liu H, Yu Q, Tam W, Lee S. A phase Ib/II study of pacritinib, an interleukin 1 receptor associated kinase 1 (IRAK1) inhibitor, in patients (pts) with solid tumors harboring the 1q21.3 copy number amplification (CNA). Journal Of Clinical Oncology 2024, 42: 43-43. DOI: 10.1200/jco.2024.42.23_suppl.43.Peer-Reviewed Original ResearchProgression-free survivalT cell populationsCD8+ T cell populationsCopy number amplificationInterleukin-1 receptor-associated kinase 1Solid tumorsTumor microenvironmentCell populationsDose levelsCD4+ T cell populationRecommended phase II dosePlasma cell-free DNAPeripheral blood mononuclear cells analysisSystemic immune modulationPhase II doseRefractory solid tumorsPhase Ib/II clinical trialDose-expansion cohortDendritic cell populationsMyeloid cell populationsTumor biopsy samplesImmune cell populationsDecreased tumor growthModulated immune cell populationsPreclinical animal modelsCHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor.
Hirano H, Naito Y, Sundar R, Komatsu Y, Kurokawa Y, Li J, Ozaka M, Iwatsuki M, Chen J, Yen C, Zalcberg J, Roy A, Chen L, Nishida T, Doi T. CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor. Journal Of Clinical Oncology 2024, 42: tps97-tps97. DOI: 10.1200/jco.2024.42.23_suppl.tps97.Peer-Reviewed Original ResearchDose-escalation partGastrointestinal stromal tumorsProgression-free survivalDays on/2 daysResistance to IMStromal tumorsImatinib-refractory gastrointestinal stromal tumorsInvestigator-assessed progression-free survivalAdvanced gastrointestinal stromal tumorsKinase-domain mutationsOvercome IM resistanceWeeks on/2 weeksDisease control rateDose-limiting toxicitySecond-line settingDuration of responseMaximum tolerated dosePhase I studyPhase 3 studyPhase 1 studySoft tissue sarcomasHsp90 inhibitorsInhibited tumor growthAnti-tumor activityOverall survivalImmunogenicity of Abdala COVID-19 vaccine in Vietnamese people after primary and booster vaccinations: a prospective observational study in Vietnam
Thanh T, Tu N, Nguyet L, Thuy C, Thuan N, Ny N, Nhu L, Thanh L, Hong N, Anh N, Truong N, Van Vinh Chau N, Yen L, Van E P, Thuong N, Van Truc N, Trung P, Yap W, Pandey R, Yee S, Weng R, Mongkolsapaya J, Dejnirattisai W, Hamers R, Chantratita N, Screaton G, Dunachie S, Jones E, Stuart D, Dung N, Thwaites G, Wang L, Tan C, Van Tan L, Wang L, Cruz K, Yee S, Lu H, Ruifen W, Pandey R, Young B, Sundar R, Soebandrio A, Sawitri A, Sutarsa I, Chan Y, Jantarabenjakul W, Chan N, Tan C, Van Tan L, Anh N, Hong N, Truc T, Ny N, Han D, Thanh L, Nguyet L, Thuy C, Nhu L, Thanh T, Yen L, Hang V, Kieu P, Hoang V, Thao N, Chambers M, Thanh V, Hoang T, van Doorn H, Tung T, Thwaites C, Thwaites G, Wang L, Lim B, Hamers R, Shankar A, Suwarti S, Tayipto Y, Simarmata E, Dien R, Mongkolsapaya J, Dejnirattisai W, Chantima W, Chantratita N, Poolchanuan P, Tiacharoen V, Dulsuk A, Iamsirithaworn S, Day N, Cheah P, Poomchaichote T, Boonthaworn K, Screaton G, Dijokaite-Guraliuc A, Das R, Liu C, Supasa P, Selvaraj M, Dunachie S, Klenerman P, Jones E, Stuart D, Kronsteiner-Dobramysl B, Zewdie M, Abraham P, Hill J, Ngoc N, Grifoni A, Sette A, Yap W, Tan C, Van Tan L. Immunogenicity of Abdala COVID-19 vaccine in Vietnamese people after primary and booster vaccinations: a prospective observational study in Vietnam. International Journal Of Infectious Diseases 2024, 107173. PMID: 39094762, DOI: 10.1016/j.ijid.2024.107173.Peer-Reviewed Original ResearchSARS-CoV-2 variantsSARS-CoV-2Neutralizing antibodiesBooster doseCOVID-19 vaccineCross-neutralizationAntibody responseMeasured anti-nucleocapsidVietnamese healthcare workersBooster vaccinationSARS-CoV-1Ancestral SARS-CoV-2Anti-spike antibodiesProspective observational studyCross-neutralizing activityProtein subunit vaccinesEnhanced antibody responseNeutralizing antibody titersMRNA BNT162b2ChAdOx1 vaccineAnti-spikeAnti-nucleocapsidPrimary vaccinationCollected blood samplesObservational studyProofreading the way: immune checkpoint inhibitors in polymerase ε/polymerase δ (POLE/POLD1)-altered colorectal cancer
Cecchini M, Sundar R. Proofreading the way: immune checkpoint inhibitors in polymerase ε/polymerase δ (POLE/POLD1)-altered colorectal cancer. Annals Of Oncology 2024, 35: 582-584. PMID: 38910015, DOI: 10.1016/j.annonc.2024.04.006.Peer-Reviewed Original ResearchState-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care.
Balmaceda N, Petrillo A, Krishnan M, Zhao J, Kim S, Klute K, Sundar R. State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care. American Society Of Clinical Oncology Educational Book 2024, 44: e431060. PMID: 38771996, DOI: 10.1200/edbk_431060.Peer-Reviewed Original ResearchConceptsGastroesophageal cancerIntegration of immune checkpoint inhibitorsChimeric antigen receptor T cellsImmune checkpoint inhibitorsMetastatic gastroesophageal cancerPD-1 inhibitorsAdoptive cell therapyImmunotherapy-based approachesResectable gastroesophageal cancerAntibody-drug conjugatesCheckpoint inhibitorsPD-1Perioperative chemotherapyTargeted therapyT cellsTreatment paradigmFGFR2 inhibitorsCell therapyClinical challengeBispecific antibodiesImprove outcomesCancer treatmentReduced toxicityTherapyInhibitorsA phase Ib/II study of an anti-CD137 agonist antibody ADG106 in combination with weekly paclitaxel and dose-dense doxorubicin/cyclophosphamide.
Lee M, Ow S, Wong A, Lim S, Lim J, Soo R, Cheng Ean C, Tan D, Yong W, Chan G, Ho J, Sooi K, Low Q, Ang C, Cheo S, Sundar R, Goh B, Lee S. A phase Ib/II study of an anti-CD137 agonist antibody ADG106 in combination with weekly paclitaxel and dose-dense doxorubicin/cyclophosphamide. Journal Of Clinical Oncology 2024, 42: e14507-e14507. DOI: 10.1200/jco.2024.42.16_suppl.e14507.Peer-Reviewed Original ResearchAdverse eventsG3 neutropeniaTumor biopsiesWeekly PPeripheral neuropathyHER2 negative breast cancer patientsPhase IbDose levelsRecommended phase 2 doseAll-grade adverse eventsNegative breast cancer patientsMatched tumor biopsiesPhase 2 doseTumor immune markersPneumocystis jiroveci pneumoniaAdvanced solid tumorsPalliative systemic therapyPhase Ib trialPhase II trialPhase IISerial tumor biopsiesBreast cancer patientsIgG4 monoclonal antibodyAcneiform rashAnti-CD137Molecular profiling of metastatic breast cancer and target-based therapeutic matching in an Asian tertiary phase I oncology unit
Walsh R, Ong R, Cheo S, Low P, Jayagopal A, Lee M, Ngoi N, Ow S, Wong A, Lim S, Lim Y, Heong V, Sundar R, Soo R, Chee C, Yong W, Goh B, Lee S, Tan D, Lim J. Molecular profiling of metastatic breast cancer and target-based therapeutic matching in an Asian tertiary phase I oncology unit. Frontiers In Oncology 2024, 14: 1342346. PMID: 38812774, PMCID: PMC11133600, DOI: 10.3389/fonc.2024.1342346.Peer-Reviewed Original ResearchProlonged median progression-free survivalTumor mutational burdenObjective response rateMetastatic breast cancerHazard ratioNext-generation sequencingPhase I unitMedian OSMolecular profilingOverall survivalAssociated with prolonged median PFSBreast cancerMedian progression-free survivalTreatment outcomesTrials of targeted therapiesProgression-free survivalData cut-offBroad-panel next-generation sequencingTumor molecular profilingTreatment eventsFoundationOne CDxMBC patientsMutational burdenAssociated with improvementsTertiary centre